arrow
M

Marcus D'Souza

university of basel
H指数:26
被引数:2,294

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A community-validated tool for clinical outcome calculation in multiple sclerosis: Consensus development and scenario-specific recommendations

一种用于多发性硬化症临床结局计算的社区验证工具:共识制定和特定场景建议

2026-08-220
PRE
Retinal layers prognosticate cognitive progression independent of relapse activity in multiple sclerosis

视网膜层预测多发性硬化认知进展,独立于复发活动

2026-08-060
OA
Emerging CSF and Serum Biomarkers in Multiple Sclerosis

多发性硬化中新兴的脑脊液和血清生物标志物

2026-05-010
PRE
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

血清神经丝轻链在多发性硬化中的研究:年龄和BMI校正的Z分数/百分位数对预测治疗反应优于绝对截断值

2025-08-030
OAAI
Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial

单音弦音乐疗法在多发性硬化症中的应用(“MUTIMS”): <i>一项随机、对照、评估者盲法的试验</i>

2025-07-080
OA
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort

特立氟胺和奥瑞利珠单抗对多发性硬化潜隐性活动比较效果:一项在瑞士多发性硬化队列中的观察性研究

2025-07-020
OAAI
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis
2025-03-010
PRE
Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis
2024-12-200
OAAI
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis

血清胶质纤维酸性蛋白和神经丝轻链水平反映了多发性硬化b细胞耗竭治疗下疾病进展的不同机制

2024-10-164
OA
Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus

多发性硬化症的视觉诱发电位: P100潜伏期和视觉通路损伤,包括外侧膝状核

2024-05-011
OAAI
Complement Activation Is Associated With Disease Severity in Multiple Sclerosis
2024-03-018
OA
Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS
2024-01-0923
OAAI
Determine atrial fibrillation burden with a photoplethysmographic mobile sensor: the atrial fibrillation burden trial: detection and quantification of episodes of atrial fibrillation using a cloud analytics service connected to a wearable with photoplethysmographic sensor
2023-07-067
OAAI
Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression
2023-04-250
PRE